Ipsen
ENXTPA:IPN Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
WA
Consensus Narrative from 15 Analysts
Cabometyx And Tovorafenib Approvals May Strengthen Oncology Portfolio In 2025
Key Takeaways Expansion of Onivyde and new product approvals could significantly increase revenue and strengthen market positions in key medical segments. Strategic acquisitions and external innovation plans aim to enhance margins and drive top-line growth through integration of high-performing assets.
View narrative€127.60
FV
13.0% undervalued intrinsic discount5.82%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
2 days ago author updated this narrative